Showing 521-530 of 1330 results for "".
- Regenerative Medicine in Action: Turn Bio's ERA Technology Reprograms Skin Cellshttps://practicaldermatology.com/news/regenerative-medicine-in-action-turn-bios-era-technology-reprograms-skin-cells/2461930/Reprogramming with Turn Bio's ERA technology can rejuvenate cells within the extracellular matrix (ECM), resulting in changes related to improved skin quality and structure, according to a presentation at the AAD 2023 Innovation Academy in Tampa, Fla. ERA reprogramming tec
- MRF to Host the 2023 Philadelphia Miles for Melanoma 5Khttps://practicaldermatology.com/news/mrf-to-host-the-2023-philadelphia-miles-for-melanoma-5k/2461928/The Melanoma Research Foundation’s (MRF) nextl Miles for Melanoma nationwide 5K program will take place in Philadelphia event on Saturday, August 26, 2023, at the Philadelphia Zoo at 7:30am ET. Register to attend the Philadelphia Miles for Melanoma 5K event
- Verrica's Injectable Oncolytic Peptide Clears BCC in Early Phase 2 Datahttps://practicaldermatology.com/news/verricas-injectable-oncolytic-peptide-clears-bcc-in-early-phase-2-data/2461925/Verrica Pharmaceuticals Inc.’s VP-315 can clear basal cell carcinoma (BCC), according to data from Part 1 of an ongoing Phase 2 study presented at the 2023 American Academy of Dermatology Innovation Academy in Tampa, Fla. Given via injection into the tumor, VP-315 is an oncolytic
- DermaSensor Device Can Help Detect Skin Cancer Across Skin Toneshttps://practicaldermatology.com/news/dermasensor-device-can-help-detect-skin-cancer-across-skin-tones/2461924/DermaSensor's handheld Elastic Scattering Spectroscopy (ESS) device can help detect skin cancer in patients across different Fitzpatrick skin types, according to new research presented at the 2023 American Academy of Dermatology (AAD) Innovation Academy meeting. DermaSensor is desig
- The Dermatology Practice of the Future: AI-Powered Piction Health Dermatology Launches in Massachusettshttps://practicaldermatology.com/news/the-dermatology-practice-of-the-future-ai-powered-piction-health-dermatology-launches-in-mass/2461923/Piction Health Dermatology, an AI-enabled dermatology virtual clinic, is now open for Massachusetts residents. Piction's virtual clinic merges artificial intelligence (AI) with the expertise of board-certified dermatologists. Patients complete a short medical in
- UF Researcher Recognized for Life’s Work on Neurofibromatosishttps://practicaldermatology.com/news/uf-researcher-recognized-for-lifes-work-on-neurofibromatosis/2461922/Margaret “Peggy” Wallace, PhD, a professor in the department of molecular genetics and microbiology in the University of Florida College of Medicine, has received an award from the Children’s Tumor Foundation in recognition of her significant contributions to neurofibromatosis r
- Positive Topline Data Seen in Phase II Trial of LNK01001 in ADhttps://practicaldermatology.com/news/positive-topline-data-seen-in-phase-ii-trial-of-lnk01001-in-ad/2461916/Lynk Pharmaceuticals Co., Ltd.’s LNK01001 performed well in a Phase II clinical trial for the treatment of atopic dermatitis (AD), according to positive topline data from the Company. LNK01001 is a highly selective JAK1 inhibitor that blocks JAK1 without crossing over onto ot
- Evolus Rolls Out New Branding for Jeuveauhttps://practicaldermatology.com/news/evolus-rolls-out-new-branding-for-jeuveau/2461913/Evolus, Inc. is unveiling its new branding for Jeuveau (prabotulinumtoxinA-xvfs). The new Jeuveau imagery reflects today’s consumers, many of whom are millennials and younger. The “Jeuveau, You See Me” marketing campaign uses inclusive messaging to encourage
- Vacation Tanning Linked to Acute Changes in Skin Microbiomehttps://practicaldermatology.com/news/vacation-tanning-linked-to-acute-changes-in-skin-microbiome/2461912/Sun-seeking behaviors while on vacation may affect the skin’s microbiome, new research suggests. Prior to vacations to sunny destinations, which lasted at least seven days, the researchers analyzed participants’ skin. On day one, 28, and 84 post-holiday, participants’
- Replimune, Incyte Enter Into Clinical Trial Collaboration And Supply Agreement To Evaluate RP1 and INCB99280 in CSCChttps://practicaldermatology.com/news/replimune-incyte-enter-into-clinical-trial-collaboration-and-supply-agreement-to-evaluate-rp1-and-incb99280-in-cscc/2461908/Replimune Group, Inc. and Incyte are collaborating to a study RP1 in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor, in cutaneous squamous cell carcinoma (CSCC) and in other cancer types,